Dysmenorrhea and Endometriosis in Transgender Adolescents

Jessica Y Shim, Laufer MR, Marc R Laufer, Frances Grimstad, Frances W Grimstad, Grimstad FW
Journal of pediatric and adolescent gynecology · 2020 · vol. 33(5) , pp. 524–528 · doi:10.1016/j.jpag.2020.06.001 · PMID:32535219 · W3034614474
article OA: closed CC0 ⤵ 26 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper examines the prevalence and clinical presentation of dysmenorrhea and endometriosis in transgender adolescents.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Study objectiveTo study the presentation of dysmenorrhea and endometriosis in transmasculine adolescents and review their treatment outcomes.DesignA retrospective review.SettingBoston Children's Hospital.ParticipantsTransmasculine persons younger than 26 years old who were diagnosed with dysmenorrhea and treated between January 1, 2000 and March 1, 2020.InterventionsNot applicable.Main outcome measuresAn electronic medical record review of the clinical characteristics, transition-related care, and treatment outcomes.ResultsDysmenorrhea was diagnosed in 35 transmasculine persons. Mean age was 14.9 years ± 1.9 years. Twenty-nine (82.9%) were diagnosed after social transition. Twenty-three of 35 (65.7%) were first treated with combined oral contraceptives, but 14/23 (61%) discontinued or transitioned to alternative therapy. Twelve patients with dysmenorrhea alone initiated testosterone treatment, and 4/12 (33.3%) experienced persistent symptoms. Seven of 35 patients with dysmenorrhea (20.0%) were laparoscopically evaluated for endometriosis, and it was confirmed in all seven. Six had stage I disease, and one had stage II. Three of the 7 (42.9%) were diagnosed after social transition, with one diagnosed 20 months after initiating testosterone treatment. Their endometriosis was treated with combined oral contraceptives, danazol, or progestins; four experienced suboptimal response during treatment with these therapies alone. Two of those with suboptimal response subsequently resolved their dysmenorrhea when using testosterone. Five patients with endometriosis initiated testosterone treatment, and of the 5 (40%) experienced persistent symptomatology with combined testosterone and progestin therapies.ConclusionTo our knowledge, this is the first study to characterize endometriosis in transmasculine persons. Evaluation for endometriosis was underutilized in transmasculine persons with dysmenorrhea, despite those who underwent laparoscopic evaluation and had disease confirmation. Although testosterone treatment can resolve symptoms in some, others might require additional suppression. Endometriosis should be considered in transmasculine persons with symptoms even when they are using testosterone.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosis

MeSH descriptors

Dysmenorrhea Endometriosis Testosterone Transgender Persons Adolescent Adult Boston Contraceptives, Oral, Combined Contraceptives, Oral, Combined Danazol Danazol Dysmenorrhea Dysmenorrhea Endometriosis Endometriosis Female Humans Male Retrospective Studies Testosterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Cited by (26)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:59.141895+00:00
License: CC0 · commercial use OK